Article
Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Hepatology (Baltimore, Md.) - 1 Sept 1997
Tong M J, Reddy K R, Lee W M, Pockros P J, Hoefs J C, Keeffe E B, Hollinger F B, Hathcote E J, White H, Foust R T, Jensen D M, Krawitt E L, Fromm H, Black M, Blatt L M, Klein M, Lubina J
Abstract excerpt
This multicenter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C infection compared treatment with consensus interferon (CIFN), a non-natural recombinant type-1 interferon, with a standard regimen of recombinant interferon alfa-2b (IFN-alpha2b). Patients were randomized to receive CIFN at doses of 3 microg or 9 microg, or 15 microg IFN-alpha2b (3 million units),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.